These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32040243)

  • 21. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review.
    Gentile G; Andreoni M; Antonelli G; Sarmati L
    Clin Microbiol Infect; 2017 Dec; 23(12):916-923. PubMed ID: 28668465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
    Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R
    Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
    Idilman R; Arat M; Soydan E; Törüner M; Soykan I; Akbulut H; Arslan O; Ozcan M; Türkyilmaz AR; Bozdayi M; Karayalçin S; Van Thiel DH; Ozden A; Beksaç M; Akan H
    J Viral Hepat; 2004 Mar; 11(2):141-7. PubMed ID: 14996349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
    Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
    Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
    Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
    Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
    Su J; Long L; Zou K
    Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues.
    Yağci M; Acar K; Sucak GT; Aki Z; Bozdayi G; Haznedar R
    Leuk Lymphoma; 2006 Aug; 47(8):1608-12. PubMed ID: 16966273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis.
    Yin S; Zhang F; Wu J; Lin T; Wang X
    PLoS Med; 2023 Mar; 20(3):e1004196. PubMed ID: 36920988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
    Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
    J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
    Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review.
    Yan Z; Luo XF; Yao SN; Wang HY; Chu JF; Zhao S; Song M; Wei XD; Zhou KS; Li YF; Zhou WP; Zhang JY; Zhang PP; Zhou LL; Wang XW; Yao ZH; Liu YY
    J Microbiol Immunol Infect; 2023 Aug; 56(4):747-756. PubMed ID: 37080838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.
    Barone M
    World J Gastroenterol; 2024 Jul; 30(25):3147-3151. PubMed ID: 39006388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
    Liu S; He Z; Wu W; Jin H; Cui Y
    Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.